VIDEO: Targeted therapies, CELMoDs in development for multiple myeloma

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We have a lot of new types of therapies in development, which is really exciting. So some of the most recent approved agents in myeloma are bispecific T-cell engagers and CAR T-cell therapy that target both BCMA or B-cell maturation antigen on the surface of myeloma cells, or something called GPRC5D, which is G-protein coupled with receptor 5D, which is the target for talquetamab (Talvey, Janssen), which is a bispecific. So those are in the new space. There's a lot of trials looking at those drugs, those bispecifics in combination and in different scenarios. So upfront, early relapse, maintenance, et cetera, used as bridging to CAR T, but we also have new drugs looking at different mechanisms of actions using those targets. So things like GPRC5D antibody drug conjugates, or BCMA antibody drug conjugates.

We also have things like trispecifics, meaning looking at a CD3, one of those targets and a second target, or maybe even CD38, so trying to use three different targets on myeloma cells to induce a response. There are also drugs in the pipeline looking at completely different mechanisms of action. So another exciting class of drugs is something called CELMoDs, which are essentially souped up IMiDs. So there's two in development, iberdomide and mezigdomide, which show incredible potency, increased potency, and importantly, improved efficacy. A really good safety profile, even in very heavily treated patients. So we're looking at that in relapse space in combination with other approved myeloma agents, and with everything else, we're looking at that on an earlier basis so there are ongoing clinical trials looking at iberdomide in smoldering myeloma, in newly diagnosed transplant ineligible, and even maintenance post-transplant.